HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?

Abstract

References

UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-58.

Matthews, DR , Hosker, JP , Rudenski , AS , et al. (1985) Homeostasis Model Assessment (HOMA): insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-19.

Kahn, SE , Haffner, SM , Heise, MA , et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide mono-therapy. N Engl J Med 355: 2427-43.

Turner, RC , Cull, CA , Fright, V. , Holman, RR for the UK Prospective Diabetes Study Group (1999) Glycemic control with diet, sulfonuylurea, metformin, or insulin in patients with type 2 diabetes: Progressive requirement of multiple therapies (UKPDS 49). JAMA 281: 2005-12.

Dupre, J. (1970) Regulation of the secretions of the pancreas. Ann Rev Med 21: 299-316

Peterson, DT , Reaven, GM (1971) Evidence that glucose load is an important determinant of plasma insulin response in normal subjects . Diabetes 20: 729-33.

Hollenbeck, C. , Reaven, GM (1987) Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64: 1169-73.

Jones, NO , Pei, D. , Staris, P. , et al. (1997) Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82: 1834-38

Byrne, MM , Sturis, J, Polonsky , (1995) Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol 268: E21-E27.

10.

Reaven, GM , Chen, Y-DI , Hollenbeck, CB , Sheu, WHH , Ostrega, D. , Polonsky, KS (1993) Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance . J Clin Endocrinol Metab 76: 44-8.

11.

Reaven, GM , Hollenbeck, C. , Jeng, C-Y. , Wu, M-S. , Chen, Y-DI (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37: 1020-24.

12.

Andrews, WJ , Vasquez, B. , Nagulesparan , M. , et al. (1984) Insulin therapy in obese, non-insulin dependent diabetes induces improvements in insulin action and secretin that are maintained for two weeks after insulin withdrawal. Diabetes 33: 634-42.

13.

Liu, G. , Coulston, AM , Lardinois , CK , Hollenbeck, CB , Moore, J. , Reaven, G. (1985) Moderate weight loss and sulfonylurea treatment of non-insulin dependent diabetes mellitus: Combined effects. Arch Int Med 145: 665-69.

14.

Reaven, G. and the staff of the Palo Alto GRECC Study Unit. (1985) Beneficial effect of moderate weight loss in older patients with non-insulin dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc 33: 93-5.

15.

Reaven, G. , Dray, J. (1967) Effect of chlorpropamide on seru glucose and immunoreactive insulin concentrations in patients with maturity onset dabetes. Diabetes 15: 487-92.

16.

Shenfield, GM , Logan, A. , Shirling , D. , Baird, J. (1977) Plasma insulin and glucose levels in maturity onset diabetes treated with chlorporpramide. Diabetologia 13: 367-71.

17.

Reaven, GM (1995) Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. Diab/Metab Rev 11: S97-S108.

18.

Chu, JW , Abbasi, F. , Lamendola , C. , McLaughlin, T. , Reaven, GM , Tsao, PS (2005) Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2: 37-41.